| Â |
BRAF
|
HRAS
|
KRAS
|
NRAS
|
PIK3CA
|
KIT
| CM (%)b |
|---|
BRAF
| 1c | 3 | 1 | 4 | 5 | 5 | 18 (10%) |
HRAS
| 3 | 0 | 1 | 0 | 1 | 1 | 6 (67%) |
KRAS
| 1 | 1 | 0 | 1 | 0 | 0 | 3 (25%) |
NRAS
| 4 | 0 | 1 | 2d | 2 | 1 | 9 (8.1%) |
PIK3CA
| 5 | 1 | 0 | 2 | 1 | 1 | 9 (75%) |
KIT
| 5 | 1 | 0 | 1 | 1 | 2e | 8 (36%) |
- aIncluding 29 tumors with 2 mutations and 2 tumors with 3 mutations
- bCoexisting mutation (CM) within different genes
- cp.S605I with unknown kinase activity and p.V600E within the same allele
- dOne with NRAS p.Q61L and p.Y64D of unknown activating status, and one with NRAS p.G13D, p.Q61K and PIK3CA p.E542G
- eOne with p.V560A and p.N822Y, and one with p.P573S, p.F681I and p.N822I
